Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sellas Life Sciences Group
Eastern Cooperative Oncology Group
University of Giessen
National Cancer Institute (NCI)
Novartis
SWOG Cancer Research Network
Children's Oncology Group
National Cancer Institute (NCI)